Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency
American Journal of Therapeutics · 2023
DOI: 10.1097/mjt.0000000000001663 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift American Journal of Therapeutics, 2023. Verfasst von Josef Wills und 4 weiteren Autor:innen. Beteiligte Einrichtung: Global Scientific Communications Rare Blood Disorders, Sanofi, Cambridge, MA. Hauptthemen laut MEDLINE: Anemia, Hemolytic, Congenital Nonspherocytic, Anemia, Hemolytic, Quinolones, Anemia, Sickle Cell. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background: Pyruvate kinase (PK) deficiency is a rare enzyme-linked glycolytic defect resulting in mild-to-severe chronic persistent erythrocyte hemolysis. The disease is an autosomal recessive trait caused by mutations in the PK liver and red blood cell gene characterized by insufficient erythrocyte PK activity. PK deficiency is most diagnosed in persons of northern European descent and managed with packed red blood cell transfusions, chelation, and splenectomy with cholecystectomy. Mitapivat is the first approved therapy indicated for hemolytic anemia in adults with PK deficiency with the potential for delaying splenectomy in mild–moderate disease. Mechanism of Action, Pharmacodynamics, and Pharmacokinetics: Mitapivat is a PK activator that acts by allosterically binding to the PK tetramer and increases PK activity. The red blood cell form of PK is mutated in PK deficiency, which leads to reduced adenosine triphosphate, shortened red blood cell lifespan, and chronic hemolysis. The half-life of elimination is 3–5 hours, with 73% bioavailability, 98% plasma protein binding, and a median duration of response of 7 months. Clinical Trials: Mitapivat has been investigated through various clinical trials for different therapeutic indications. Pivotal trials that serve the primary focus throughout this article are ACTIVATE, ACTIVATE-T, and RISE. ACTIVATE is a phase 3, randomized, double-blind, placebo-controlled study that evaluated the efficacy and safety of mitapivat in adult patients who were not receiving regular blood transfusions. Contrarily, ACTIVATE-T explored the safety and efficacy of mitapivat in adults with PK deficiency who received regular blood transfusions. Both trials demonstrated favorable use of mitapivat in PK deficiency. Focusing on another indication, the ongoing RISE trial investigates the optimal dosage of mitapivat in sickle cell disease. Therapeutic Advance: Mitapivat is an appropriate treatment for adults with PK deficiency requiring transfusions and may be considered for patients with symptomatic anemia who do not require transfusions and/or PK deficiency with compensated hemolysis without overt anemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Global Scientific Communications Rare Blood Disorders, Sanofi, Cambridge, MA.
- Gastroenterology, Dupilumab, Sanofi, Cambridge, MA.
- Massachusetts College of Pharmacy and Health Sciences, School of Pharmacy, Worcester, MA.
- Transilvania University, Faculty of Medicine, Department of Fundamental Disciplines and Clinical Prevention, Brasov, Romania.
ORCID-Profile: Lorena Dima
Zitieren
APA
Wills, J., Horenstein, M., Kim, A., Silva, M. A., & Dima, L. (2023). Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency. American Journal of Therapeutics. https://doi.org/10.1097/mjt.0000000000001663
Vancouver
Wills J, Horenstein M, Kim A, Silva MA, Dima L. Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency. American Journal of Therapeutics. 2023. doi:10.1097/mjt.0000000000001663
BibTeX
@article{Wills2023,
author = {Wills, Josef and Horenstein, Melissa and Kim, Alicia and Silva, Matthew A and Dima, Lorena},
title = {Mitapivat: A Quinolone Sulfonamide to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency},
journal = {American Journal of Therapeutics},
year = {2023},
doi = {10.1097/mjt.0000000000001663}
}
EUVIMED